KLUS Pharma to Present at BIO Digital

KLUS Pharma will attend BIO Digital from June 8-12, 2020 and present recent data for its anti-TROP2 antibody-drug conjugate (ADC). KLUS Pharma is a private company founded in 2014 and is based in New Jersey with 50 employees. The company is developing innovative antibody-based therapeutics for oncology, including monoclonal and bispecific antibodies, and antibody-drug conjugates. The company is currently seeking interested partners to help develop its innovative drug pipeline.

SKB264 is an antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2). Our proprietary conjugation chemistry and novel cytotoxic payload enables a high DAR (drug-to-antibody ratio) to be achieved. Non-clinical studies showed significant anti-tumor activity in animal models of breast cancer, gastric cancer, lung cancer, and colorectal cancer with overexpression of TROP2. The product was well tolerated with a good safety profile. The manufacturing process showed high stability, controllability, scalability, and batch-to-batch consistency. SKB264 has received IND/CTA clearance from the FDA and NMPA to begin Phase 1 clinical trials in the US and China, and we are currently recruiting patients for the Phase 1 study.

More detailed information will be presented at BIO Digital 2020.